Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...
As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...
Antioxidant-1 may promote HCC carcinogenesis through the activation of the c-Myb/PI3K/AKT pathway and the inhibition of copper accumulation and oxidative stress. Despite advancements in diagnostic and ...
Pretreatment tumor was evaluated from operable TNBC patients enrolled on a clinical trial of neoadjuvant therapy (NAT; A Robust TNBC Evaluation fraMework to Improve Survival [ClinicalTrials.gov ...
Experts in cell signaling at the Babraham Institute have identified how prostate cancer cells achieve cell growth free from the usual growth cues and regulators. This discovery has implications for ...
Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway ...
Zovegalisib (RLY-2608) is the first pan-mutant-selective PI3Kα inhibitor, binding a novel allosteric site distinct from ...
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study A total of 3.4% (41/1,206) of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results